EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global le

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Merit Me

Wall Street analysts upgraded AJG & BRC. See analyst rating changes & how they view BRC stoc

Barclays analyst Luke Sergott upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to

Stephens & Co. analyst Steven Etoch reiterates West Pharmaceutical Servs (NYSE:WST) with a Ov

Morgan Stanley analyst Kallum Titchmarsh maintains West Pharmaceutical Servs (NYSE:WST) with a Eq

Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced

West Pharmaceutical disclosed a cyberattack that disrupted operations as analysts assess financial r

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight

West Pharmaceutical beats Q1 estimates on strong GLP-1 demand, raises 2026 outlook, and authorizes $

U.S. stocks dipped as Iran-Hormuz tensions lifted oil, IBM and ServiceNow cratered, and defensive se

U.S. stocks were lower on Thursday, with the Dow Jones dropping over 200 points. Comcast's stron

WST: 16% | West Pharmaceutical Services shares are trading higher after the company reported better-

West Pharmaceutical Servs (NYSE:WST) is looking for Q2 Adj EPS of $2.05-$2.12 vs $2.00 analyst estim

West Pharmaceutical Servs (NYSE:WST) sees Q2 sales of $830.000 million-$850.000 million vs $818.537

Outlook for Full-Year and Second Quarter 2026Full-year 2026 net sales guidance increased to a range

West Pharmaceutical Servs (NYSE:WST) raises FY2026 GAAP EPS guidance from $7.79-$8.14 to $8.15-$8.50

West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.13 per share which beat the a

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight

U.S. stocks rose broadly on Tuesday as crude oil plunges over 10% on Trump's Iran end-of-war sig

West Pharmaceutical Services, Inc. (NYSE:WST) announced today that Eric M. Green has informed the Bo

On February 17, 2026, the Board of Directors authorized a new share repurchase program for the purch

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight

West Pharmaceutical Servs (NYSE:WST) is looking for FY2026 Adj EPS of $7.85-$8.20 vs $7.78 analyst e

West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.04 per share which beat the a

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a

Last week's biggest large-cap decliners included AeroVironment, DraftKings, AppLovin and Abbott,

AbbVie agrees to lower drug prices, invest $100 billion in the U.S., expand manufacturing, and secur

AbbVie (NYSE:ABBV) and West Pharmaceutical Services (NYSE:WST) announced today a definitive agreemen

Morgan Stanley analyst Kallum Titchmarsh initiates coverage on West Pharmaceutical Servs (NYSE:WS

TD Cowen analyst Brendan Smith initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight

 West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectab

UBS analyst John Sourbeer maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises th

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a

Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's

West Pharmaceutical posts Q3 earnings of $1.96 per share and raises 2025 guidance, driven by GLP-1 d

Medpace, ICON, and West Pharma led last week's large-cap rally, driven by strong earnings beats